Literature DB >> 11282179

Persistence of Trypanosoma cruzi in chronic chagasic cardiopathy patients.

V Monteón-Padilla1, N Hernández-Becerril, M A Ballinas-Verdugo, A Aranda-Fraustro, P A Reyes.   

Abstract

BACKGROUND: Although patients with chronic chagasic cardiopathy do have a strong immune response against Trypanosoma cruzi, they have transient and low parasitemia as well as tissue amastigote nests. When conventional studies were carried out, demonstration of such abnormalities is minimally achieved. Molecular biology may provide the best tools to demonstrate parasite persistence, which could be pathogenic in this progressive disease.
METHODS: We studied 16 patients with chronic chagasic cardiopathy (CCC) at the Instituto Nacional de Cardiología Ignacio Chávez in Mexico City. Patients had undergone a complete clinical evaluation, and had antibodies against Trypanosoma cruzi. They came from different rural areas in Mexico. Blood samples were obtained and processed for hemoculture and PCR technique. A CCC necropsy case was also sought for the presence of parasite antigen or DNA, using immunohistochemistry and PCR methods in archival tissues.
RESULTS: Five of 16 (31%) hemocultures demonstrated circulating T. cruzi; 60% occurred in persons between 25 and 40 years old. In contrast, we found a positive PCR amplification in 81%; therefore, molecular biology tools appear to be more sensitive for demonstrating parasite persistence. There were no correlations between parasitemic state and clinical findings or specific antibody titer. The autopsy case had parasite antigens and DNA in heart tissues.
CONCLUSIONS: Chronic chagasic cardiopathy patients do have persistence of parasite even when parasitemia is low or absent. The continuous presence of a parasite load could maintain immune stimulus and perhaps enhance a pathogenic immune or autoimmune tissue damage in susceptible hosts.

Entities:  

Mesh:

Year:  2001        PMID: 11282179     DOI: 10.1016/s0188-4409(00)00261-7

Source DB:  PubMed          Journal:  Arch Med Res        ISSN: 0188-4409            Impact factor:   2.235


  10 in total

1.  Immunotherapy of Trypanosoma cruzi infection with DNA vaccines in mice.

Authors:  Eric Dumonteil; Javier Escobedo-Ortegon; Norma Reyes-Rodriguez; Arletty Arjona-Torres; Maria Jesus Ramirez-Sierra
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

2.  Short treatment with the tumour necrosis factor-alpha blocker infliximab diminishes chronic chagasic myocarditis in rats without evidence of Trypanosoma cruzi reactivation.

Authors:  A R Pérez; G H Fontanella; A L Nocito; S Revelli; O A Bottasso
Journal:  Clin Exp Immunol       Date:  2009-08       Impact factor: 4.330

3.  Different parasite inocula determine the modulation of the immune response and outcome of experimental Trypanosoma cruzi infection.

Authors:  Diego C Borges; Natalia M Araújo; Cristina R Cardoso; Javier E Lazo Chica
Journal:  Immunology       Date:  2013-02       Impact factor: 7.397

4.  Host triacylglycerols shape the lipidome of intracellular trypanosomes and modulate their growth.

Authors:  Felipe Gazos-Lopes; Jessica L Martin; Peter C Dumoulin; Barbara A Burleigh
Journal:  PLoS Pathog       Date:  2017-12-27       Impact factor: 6.823

5.  A therapeutic vaccine prototype induces protective immunity and reduces cardiac fibrosis in a mouse model of chronic Trypanosoma cruzi infection.

Authors:  Meagan A Barry; Leroy Versteeg; Qian Wang; Jeroen Pollet; Bin Zhan; Fabian Gusovsky; Maria Elena Bottazzi; Peter J Hotez; Kathryn M Jones
Journal:  PLoS Negl Trop Dis       Date:  2019-05-30

6.  Induction of Autophagy by Ursolic Acid Promotes the Elimination of Trypanosoma cruzi Amastigotes From Macrophages and Cardiac Cells.

Authors:  María Cristina Vanrell; Santiago José Martinez; Lucila Ibel Muñoz; Betiana Nebaí Salassa; Julián Gambarte Tudela; Patricia Silvia Romano
Journal:  Front Cell Infect Microbiol       Date:  2022-07-08       Impact factor: 6.073

7.  Thromboxane A2 is a key regulator of pathogenesis during Trypanosoma cruzi infection.

Authors:  Anthony W Ashton; Shankar Mukherjee; F N U Nagajyothi; Huan Huang; Vicki L Braunstein; Mahalia S Desruisseaux; Stephen M Factor; Lillie Lopez; Joan W Berman; Murray Wittner; Philipp E Scherer; Valerie Capra; Thomas M Coffman; Charles N Serhan; Katherine Gotlinger; Kenneth K Wu; Louis M Weiss; Herbert B Tanowitz
Journal:  J Exp Med       Date:  2007-04-09       Impact factor: 14.307

8.  Exacerbated skeletal muscle inflammation and calcification in the acute phase of infection by Mexican Trypanosoma cruzi DTUI strain.

Authors:  Andrea Vizcaíno-Castillo; Andrea Jiménez-Marín; Bertha Espinoza
Journal:  Biomed Res Int       Date:  2014-06-02       Impact factor: 3.411

9.  Programmed Cell Death Protein 1-PDL1 Interaction Prevents Heart Damage in Chronic Trypanosoma cruzi Infection.

Authors:  Raíssa Fonseca; Rafael Moysés Salgado; Henrique Borges da Silva; Rogério Silva do Nascimento; Maria Regina D'Império-Lima; José Maria Alvarez
Journal:  Front Immunol       Date:  2018-05-07       Impact factor: 7.561

10.  Correlation of Parasite Burden, kDNA Integration, Autoreactive Antibodies, and Cytokine Pattern in the Pathophysiology of Chagas Disease.

Authors:  Moisés Wesley; Aline Moraes; Ana de Cássia Rosa; Juliana Lott Carvalho; Tatiana Shiroma; Tamires Vital; Nayra Dias; Bruna de Carvalho; Doralina do Amaral Rabello; Tatiana Karla Dos Santos Borges; Bruno Dallago; Nadjar Nitz; Luciana Hagström; Mariana Hecht
Journal:  Front Microbiol       Date:  2019-08-21       Impact factor: 5.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.